Select Bibliography

Filter by any of these (after searching):

CALGB-80802

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 5 items

Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)

Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016

Abstract - Primary - Primary - GI - CALGB-80802

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma

Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019

Manuscript - Primary - Primary - GI - CALGB-80802

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8)

Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802

Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative Science from CALGB 80802

Dercle, Laurent , Geyer, Susan , Nixon, Andrew , Innocenti, Federico ... - ASCO GI - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802

Alliance/CALGB 80802 impact of hepatitis c (HCV) on doxorubicin (D) + sorafenib (S) vs. s in patients (pts) advanced HCC (aHCC)

Dika, Imane El , Geyer, Susan M. , Nixon, Andrew ... - ASCO GI - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802